Background: Mean birthweight is lower in children of SLE-mothers than in references. Active disease in pregnancy is considered one of the risk factors. Objectives: The aim of this study was to explore the association of disease activity in women with SLE in pregnancy and the birth weight of the child expressed as mean birth weight and mean z-score for birth weight. Methods: We linked data from RevNatus with data from the Medical Birth Registry of Norway (MBRN). RevNatus is a Norwegian nationwide prospective observational register including women with an inflammatory rheumatic disease when planning pregnancy or after conception. The register is administered by the National advisory unit on pregnancy and rheumatic diseases. Women 18 years or older are recruited and followed-up in each trimester of pregnancy and at 6 weeks, 6 months and 12 months after birth. MBRN is a national birth registry. The population constituted all singleton live births recorded in MBRN in the period 2006 -2014. The births in women diagnosed with SLE in MBRN and included in RevNatus formed the patient group (n=180). The references were all other births (n=498849). Mean birth weight in the patient group was compared to mean birth weight in the general obstetric population. We calculated z-score for birth weight adjusted for gestational age and sex. The target population was then split in two groups according to disease activity assessed in the 2nd trimester, and compared to references. One-way ANOVA was performed to compare SLE-women without active disease, SLE-women with active disease and references from the general obstetric population. Results: The mean birth weight and mean z-score were both significantly lower in women with SLE compared to references. When comparing three groups, a significantly lower mean birth weight and mean z-score remained between women without active disease and references and women with active disease and references. There were no significant differences between the two disease groups. 
Conclusions:
Mean birth weight and Z-score was significantly lower in women with SLE compared to the general obstetric population. There were no significant differences in diseased women with active as opposed to quiescent disease. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.5820 Background: Tuberculosis (TB) is a major concern in patients receiving TNF inhibitors (TNFi). Objectives: To assess the incidence of active TB and the efficacy of TB prevention measures in a large, single-center cohort of patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) receiving TNFi. Methods: Data of all patients in whom treatment with TNFi was initiated in our rheumatology clinic from January 1st 2002 until December 31st 2015 have been retrospectively analysed. The cohort was divided into 2 groups per the mandatory latent TB infection (LTBI) screening method at baseline: tuberculin skin test (group TST), and QuantiFERON ® -TB Gold test (group QFT). The incidence of active TB was analysed for each group and compared to TB incidence data in general population. Results: 653 patients were included (344 RA, 52 PsA, 257 AS); 324 patients belonged to the TST and 329 to the QFT group. The number of active TB cases/ time of exposure to TNFi (person-years, PY) was 17/2002.6 and 7/1041.2 respectively, accounting for an incidence of 848.9 and 672.3 cases per 10 5 PY, about 8 times higher (8.3 and 8.8 for TST, respectively QFT group) than the average TB during the period of exposure to TNFi. LTBI reactivations per total TB cases were only 4/17 and 2/7, respectively, too few to identify statistically significant differences between the 2 LTBI screening protocols. Only 10 patients
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